NasdaqCM - Delayed Quote USD

Processa Pharmaceuticals, Inc. (PCSA)

2.1500 -0.2800 (-11.52%)
At close: April 26 at 4:00 PM EDT
2.1400 -0.01 (-0.47%)
After hours: April 26 at 7:58 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. George K. Ng Esq., J.D. Chief Executive Officer 400.27k -- 1974
Dr. David Young Ph.D., Pharm.D. Co-Founder, President of Research and Development & Director 160.2k -- 1953
Dr. Sian E. Bigora Ph.D., Pharm.D. Co-Founder and Chief Development & Regulatory Officer 184.87k -- 1960
Mr. James H. Stanker Chief Financial Officer 160.2k -- 1958
Mr. Patrick Lin Co-Founder, Chief Business & Strategy Officer 117.15k -- 1965
Ms. Wendy J. Guy Co-Founder, Chief Administrative Officer & Corporate Secretary 94.19k -- 1964

Processa Pharmaceuticals, Inc.

7380 Coca Cola Drive
Suite 106
Hanover, MD 21076
United States
443 776 3133 https://www.processapharmaceuticals.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
13

Description

Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

Corporate Governance

Processa Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
Processa Pharmaceuticals, Inc. Earnings Call

Related Tickers

BDRX Biodexa Pharmaceuticals Plc
1.3000
+80.56%
 
MLEC Moolec Science SA
1.4500
+2.11%
 
NKGN NKGen Biotech, Inc.
1.6100
-18.69%
 
TVGN Tevogen Bio Holdings Inc.
1.0000
+17.65%
 
PALI Palisade Bio, Inc.
6.05
-2.89%
 
ABVC ABVC BioPharma, Inc.
1.4200
-10.69%
 
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
 
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
 
CYCC Cyclacel Pharmaceuticals, Inc.
1.5100
-5.63%
 
JAGX Jaguar Health, Inc.
0.1800
+5.88%